SCHEMBL28503

SCHEMBL28503

O=C(COC1CCCCO1)c1ccccc1-c1ccc(OC2CC(O)CCO2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
TNK2 Q07912 3/20 0.37
ITGB1 P05556 1/20 0.33
ITGA4 P13612 1/20 0.33
KDM4C Q9H3R0 1/20 0.33
ACP1 P24666 1/20 0.32
GAA P10253 1/20 0.32
CHRNB2 P17787 1/20 0.31
CHRNB4 P30926 1/20 0.31
CHRNA3 P32297 1/20 0.31
CHRNA4 P43681 1/20 0.31
ICAM1 P05362 1/20 0.31
SELE P16581 1/20 0.31
ALDH1A1 P00352 1/20 0.31
LMNA P02545 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
PPARG P37231 2/20 0.31
PPARA Q07869 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11627980 0.73 MEN1 (0.42) MEN1KMT2AKDM4CICAM1SELE
SCHEMBL7137362 0.72 GAA (0.35) MEN1KMT2ATNK2ITGB1ITGA4
SCHEMBL13670675 0.70 MEN1 (0.51) MEN1KMT2ALMNAMGLL
SCHEMBL4776765 0.69 MEN1 (0.52) MEN1KMT2AKDM4CALDH1A1
SCHEMBL2125481 0.69 KMT2A (0.37) MEN1KMT2ATNK2ALDH1A1
SCHEMBL8874230 0.66 ITGB1 (0.42) ITGB1ITGA4GAACHRNB2CHRNB4
SCHEMBL24581535 0.66 TNK2 (0.37) MEN1KMT2ATNK2ITGB1ITGA4
SCHEMBL6210554 0.66 MEN1 (0.51) MEN1KMT2ALMNASMN1; SMN2
SCHEMBL6300033 0.65 MAPT (0.49) MEN1KMT2AKDM4CGAASMN1; SMN2
SCHEMBL11632207 0.64 ALDH1A1 (0.39) MEN1KMT2AKDM4CALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3682880-A1 TREATMENT OF HOT FLUSHES, VASOMOTOR SYMPTOMS, AND NIGHT SWEATS WITH SEX STEROID PRECURSORS IN COMBINATION WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS Endorecherche, Inc. (CA) 2020-07-22 EP disclosed
US-10548903-B2 Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM ENDORECHERCHE, INC. (CA) 2020-02-04 US disclosed
US-20190269697-A1 A METHOD OF TREATING AND PREVENTING LOSS OF COGNITION ENDORECHERCHE, INC. (CA) 2019-09-05 US disclosed
US-20190269696-A1 METHOD OF PREVENTING ALZHEIMIER'S DISEASE ENDORECHERCHE, INC. (CA) 2019-09-05 US disclosed
US-10342805-B2 Treatment of Alzheimer's disease, loss of cognition, memory loss and dementia with sex steroid precursors in combination with selective estrogen receptor modulators ENDORECHERCHE, INC. (CA) 2019-07-09 US disclosed
US-20170290847-A1 TREATMENT OF MALE ANDROGEN DEFICIENCY SYMPTOMS OR DISEASES WITH SEX STEROID PRECURSOR COMBINED WITH SERM ENDORECHERCHE, INC. 2017-10-12 US disclosed
US-9744177-B2 Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM ENDORECHERCHE, INC. (CA) 2017-08-29 US disclosed
EP-3178480-A1 TREATMENT OF HOT FLUSHES, VASOMOTOR SYMPTOMS, AND NIGHT SWEATS WITH SEX STEROID PRECURSORS IN COMBINATION WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS Endorecherche, Inc. (CA) 2017-06-14 EP disclosed
EP-3116510-A1 TREATMENT OF MALE ANDROGEN DEFICIENCY SYMPTOMS OR DISEASES WITH SEX STEROID PRECURSOR COMBINED WITH SERM Endorecherche, Inc. (CA) 2017-01-18 EP disclosed
WO-2015135061-A1 TREATMENT OF MALE ANDROGEN DEFICIENCY SYMPTOMS OR DISEASES WITH SEX STEROID PRECURSOR COMBINED WITH SERM ENDORECHERCHE, INC. (CA) 2015-09-17 WO disclosed
US-20040034000-A1 Methods of treating and/or suppressing insulin resistance ENDORECHERCHE, INC. 2004-02-19 US disclosed
US-6670346-B1 Treatment and/or inhibition of the development of osteoporosis, breast cancer, hypercholesterolemia, hyperlipidemia or atherosclerosis in susceptible warm-blooded animals including humans, administering selective estrogen ENDORECHERCHE, INC. (CA) 2003-12-30 US disclosed
US-20030065008-A1 Selective estrogen receptor modulators in combination with estrogens ENDORECHERCHE, INC. 2003-04-03 US disclosed
US-20030040510-A1 Selective estrogen receptor modulators in combination with estrogens ENDORECHERCHE, INC. 2003-02-27 US disclosed
US-20020198179-A1 Selective estrogen receptor modulators in combination with estrogens ENDORECHERCHE, INC. 2002-12-26 US disclosed
EP-1251855-A1 SELECTIVE ESTROGEN RECEPTOR MODULATORS IN COMBINATION WITH ESTROGENS Endorecherche, Inc. (CA) 2002-10-30 EP disclosed
US-6465445-B1 SUCH AS DERIVATIVE CONTAINING PHENYL, BENZOPHENONE AND PYRROLIDINE OR PIPERIDINE RINGS AND DEHYDROEPIANDROSTERONE; TREATMENT AND/OR INHIBITION OF OSTEOPOROSIS, BREAST CANCER, HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA OR ATHEROSCLEROSIS ENDORECHERCHE, INC. (CA) 2002-10-15 US disclosed
WO-2001054699-A1 SELECTIVE ESTROGEN RECEPTOR MODULATORS IN COMBINATION WITH ESTROGENS ENDORECHERCHE, INC. (CA) 2001-08-02 WO disclosed
EP-1083905-A2 SELECTIVE ESTROGEN RECEPTOR MODULATOR IN COMBINATION WITH DEHYDROEPIANDROSTERONE (DHEA) OR ANALOGUES Endorecherche Inc. (CA) 2001-03-21 EP disclosed
WO-1999063974-A2 SELECTIVE ESTROGEN RECEPTOR MODULATOR IN COMBINATION WITH DENYDROEPIANDROSTERONE (DHEA) OR ANALOGUES ENDORECHERCHE, INC. (CA) 1999-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034000-A1 Methods of treating and/or suppressing insulin resistance SHBG, HSD17B11, HSD17B3 MEN1 4020/4885KMT2A 4005/4885TNK2 4475/4885
US-20190269697-A1 A METHOD OF TREATING AND PREVENTING LOSS OF COGNITION SHBG, BRCA1, CYP19A1 MEN1 185/4885KMT2A 210/4885TNK2 3134/4885
US-20030065008-A1 Selective estrogen receptor modulators in combination with estrogens ESR1, BRCA1, KISS1R MEN1 54/4885KMT2A 691/4885TNK2 3158/4885
US-20020198179-A1 Selective estrogen receptor modulators in combination with estrogens KISS1R, ESR1, BRCA1 MEN1 48/4885KMT2A 716/4885TNK2 3166/4885
US-20190269696-A1 METHOD OF PREVENTING ALZHEIMIER'S DISEASE BRCA1, SHBG, CYP19A1 MEN1 97/4885KMT2A 187/4885TNK2 4303/4885
US-10342805-B2 Treatment of Alzheimer's disease, loss of cognition, memory loss and dementia with sex steroid precursors in combination with selective estrogen receptor modulators BRCA1, SHBG, CYP19A1 MEN1 224/4885KMT2A 159/4885TNK2 3091/4885
US-10548903-B2 Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM SHBG, CYP19A1, AR MEN1 837/4885KMT2A 390/4885TNK2 3223/4885
US-20170290847-A1 TREATMENT OF MALE ANDROGEN DEFICIENCY SYMPTOMS OR DISEASES WITH SEX STEROID PRECURSOR COMBINED WITH SERM SHBG, CYP19A1, AR MEN1 837/4885KMT2A 390/4885TNK2 3223/4885
US-20030040510-A1 Selective estrogen receptor modulators in combination with estrogens KISS1R, ESR1, BRCA1 MEN1 48/4885KMT2A 716/4885TNK2 3166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.